Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Atai Life Sciences 第四季度和 2023 年全年業績：現金流急劇流失但2026年的目標依然存在，Psychedelic Pipeline 的最新消息
Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full year 2023.
臨床階段的迷幻藥生物技術公司Atai Life Sciences（納斯達克股票代碼：ATAI）公佈了其第四季度和2023年全年的合併財務業績。
The Numbers:
數字：
Cash, cash equivalents and short-term investments of $154.2 million by December 31, 2023, as compared to $273.1 million by December 31, 2022.
Quarterly and full-year R&D expenses of $14.2 million and $62.2 million, respectively, as compared to $21.9 million and $74.3 million for the same periods in 2022.
Quarterly and full-year General and Administrative (G&A) expenses of $19.4 million and $63.6 million, respectively, as compared to $15.7 million and $70.4 million in the same periods in 2022.
Quarterly and full-year net loss of $18.3 million and...
截至2023年12月31日，現金、現金等價物和短期投資爲1.542億美元，而截至2022年12月31日爲2.731億美元。
季度和全年研發費用分別爲1,...
登入免費觀看全文
登入/註冊